Terrain Pharmaceuticals is pleased to confirm our commercial partnership with MEDRx Co., Ltd. (TSE Growth: 4586) for the U.S. launch of Bondlido™, an FDA-approved lidocaine patch for the relief of pain associated with post-herpetic neuralgia (PHN) in adults. Under this agreement, Terrain will serve as the exclusive U.S. commercial partner for Bondlido™, with product launch targeted for the second half of 2026.
“MEDRx has developed a truly innovative product in Bondlido™, and bringing it to U.S. patients is exactly the mission our platform was built for. Our infrastructure, pharmacy and provider relationships, and 14-year track record with topical patches give us the commercial foundation to launch this product with speed and scale. This partnership is a major win for everyone, especially Americans living with the daily burden of post-herpetic neuralgia.
JMJames Maher CEO, Terrain Pharmaceuticals
The Commercial Platform Built for This
Terrain has spent 14 years building the infrastructure required to bring specialty topical products to patients efficiently and at scale. Our nationwide network spans independent retail pharmacies, specialty pharmacies, and medical practices across the United States. We have a proven track record launching and commercializing topical patches and semisolids, including lidocaine and NSAID-based formulations, through both prescription and OTC channels. Bondlido™ fits directly into our existing therapeutic focus and channel relationships, allowing us to move quickly from agreement to patient access.